Clinical trial NCT02488408: A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS
Official title: A Phase Ib/II Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine or Decitabine in Patients With Acute Myeloid Leukemia or as a Single Agent in Patients With Myelodysplastic Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndromes
Keywords: BGB324
bemcentinib
Lead sponsor: BerGenBio ASA
Sponsor class: INDUSTRY
First posted: 2015-07-02
Enrollment: 122
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: A Phase Ib/II multicentre open label study of bemcentinib (BGB324) as a single agent in participants with Acute Myeloid Leukemia (AML) or Myelodysplastic syndrome (MDS) or in a combination with cytarabine or decitabine in AML participants.

Bemcentinib is a potent selective small molecule inhibitor of AXL a surface membrane protein kinase receptor which is overexpressed in up to half of AML cases.

Detailed description: This study is a dose-escalation of bemcentinib (BGB324), a selective AXL kinase inhibitor, in participants with AML and MDS, followed by a cohort expansion study of bemcentinib either as a single agent in participants with AML or MDS, or in combination with cytarabine (cytosine arabinoside, Ara-C) or decitabine in participants with AML.

The study will run in Germany, Norway, Italy and the US and may enrol up to approximately 90 participants with AML or MDS.

The study consisted of a dose-escalation phase to determine the MTD (maximum tolerated dose) and/or recommended dose for Phase II (RP2D) of bemcentinib in participants with relapsed or refractory AML or MDS (Part A) followed by a cohort expansion phase in five disease-specific cohorts (Part B).

Bemcentinib was administered orally according to a daily schedule, with the first three doses of Cycle 1 serving as a 'loading' dose. Each 21-day (three week) period will constitute 1 cycle of treatment.

Eligibility criteria: Inclusion Criteria:

1. Provision of signed written informed consent.
2. Histological, molecular or cytological confirmation of:

   1. Part A: Participants must have received previous treatment with cytotoxic chemotherapy (with or without hematopoietic stem cell transplantation) or a gene expression modulator, such as a demethylating agent. Participants suitable for intensive chemotherapy should be in second or subsequent relapse or be refractory to at least two induction regimens. If eligible they should have undergone hematopoietic stem cell transplantation. Participants receiving an allograft in first remission would be eligible at the time of relapse. Participants who are unsuitable for intensive chemotherapy as a result of advanced age or co-morbidities should have relapsed following at least one line of therapy or be refractory.
   2. Part B1: Participants with AML who are unsuitable for intensive chemotherapy as a result of advanced age or co-morbidities. Participants should have relapsed following at least one line of therapy or be refractory to such prior therapy. Participants should not have received standard dose intensive chemotherapy.
   3. Part B2: Participants with AML who are unsuitable for intensive chemotherapy as a result of advancing age or co-morbidities and who are suitable to receive treatment with cytarabine.
   4. Part B3: Participants with AML who are unsuitable for intensive chemotherapy as a result if advancing age or co-morbidities and who are suitable to receive treatment with decitabine.
   5. Part B4: Participants with MDS (with the exception of deletion 5q MDS) including intermediate and high-risk participants who must have received prior treatment for their disease. Prior treatment may include those participants who have received hypomethylating agents, decitabine or other approved treatments for MDS.
   6. Part B5: Participants with relapsed or refractory AML who are unsuitable for intensive chemotherapy as a result of advanced age or co-morbidities meeting the following criteria:

      * Must have received at least one prior treatment for AML Are suitable to receive treatment with "low-dose" cytarabine (LDAC). LDAC is defined as 20 mg cytarabine administered subcutaneously twice daily for 10 days every 28 days. The number of participants with refractory AML, defined as no hematological response to last AML treatment and/or participants who have received 2 or more prior treatments for AML, will be restricted to 1/3 of the sample size (i.e. no more than 6 evaluable participants).
3. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2.
4. Age 18 years or older.
5. Female participants of childbearing potential must have a negative serum pregnancy test within 3 days prior to taking their first dose of bemcentinib. Male participants and female participants of reproductive potential must practice highly effective methods of contraception (such as hormonal implants, combined oral contraceptives, injectable contraceptives, intrauterine device with hormone spirals, total sexual abstinence, vasectomy) throughout the study and for \>=3 months after the last dose of bemcentinib.

Female participants are considered NOT of childbearing potential if they have a history of surgical sterility or evidence of post-menopausal status defined as any of the following:

1. Natural menopause with last menses \>1 year ago.
2. Radiation induced oophorectomy with last menses \>1 year ago.
3. Chemotherapy induced menopause with last menses \>1 year ago.

Exclusion Criteria:

1. Participants who have a matched donor and are candidates for allogeneic bone marrow transplantation.
2. Pregnant or lactating
3. History of the following cardiac conditions:

   * Congestive cardiac failure of \>Class II severity according to the New York Heart Association (defined as symptomatic at less than ordinary levels of activity)
   * Ischemic cardiac event including myocardial infarction within 3 months prior to first dose. Participants with prior history or ECG evidence of old myocardial infarction should be discussed with the Sponsor to confirm eligibility.
   * Uncontrolled cardiac disease, including unstable angina, uncontrolled hypertension (i.e. sustained systolic BP \>160 mmHg or diastolic BP \>90 mmHg), or need to change medication within 6 weeks of provision of consent due to lack of BP control
   * History or presence of sustained bradycardia (\<=55 beats per minute), left bundle branch block, cardiac pacemaker or ventricular arrhythmia.

   Note: Participants with supraventricular arrhythmia should be discussed with the Sponsor to confirm eligibility.
   * Family history of long QTc syndrome; personal history of long QTc syndrome or previous drug-induced QTc prolongation of at least Grade 3 (QTc \>500 ms).
   * Presence of any factors that increase the risk for QTc prolongation, e.g. resistant or inadequately treated heart failure, presence of hypokalemia or hypomagnesemia not corrected by, or not responding to, replacement therapy or inadequately treated hypothyroidism as defined by the thyroid-stimulating hormone not within the expected range of the institution.
4. Abnormal left ventricular ejection fraction (less than the lower limit of normal for a participants of that age at the treating institution or \<45%, whichever is lower).
5. Current treatment with any agent known to cause QT prolongation and have a risk for Torsades de Pointes which cannot be discontinued at least 5 half-lives or 2 weeks prior to the first dose of study treatment. Please see Appendix 3 for list of relevant medications.
6. Screening 12-lead ECG with a measurable QTcF \>450 ms.
7. Ongoing infection requiring systemic treatment. participants who are on prophylactic antimicrobials or who have been afebrile for 48 hours following the initiation of antimicrobials are eligible.
8. Inadequate liver function as demonstrated by serum bilirubin \>=1.5 times the upper limits of normal range (ULN) or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>=2.5 times the ULN (or \>=5 times the ULN for AST or ALT in the presence of liver involvement by leukemia).
9. Inability to tolerate oral medication.
10. Existing gastrointestinal disease affecting drug absorption such as celiac disease or Crohn's disease.
11. Known lactose intolerance.
12. Requires vitamin K antagonists. Note: participants receiving low doses prescribed to maintain the patency of venous access devices may be included.
13. Treatment with any of the following H2 receptor antagonists, proton pump inhibitors or antacids within 3 days of administration of bemcentinib.
14. Treatment with any medication which is predominantly metabolized by CYP3A4 and has a narrow therapeutic index.
15. Previous bowel resection that would interfere with drug absorption.
16. Evidence of ongoing gastrointestinal graft versus host disease.
17. Hematopoietic stem cell transplantation within 6 months.
18. Impaired renal function as demonstrated by a creatinine clearance of \<30 mL/min determined by Cockcroft-Gault formula.
19. Radiotherapy or chemotherapy within the 14 days prior to the first dose of bemcentinib being administered (other than hydroxyurea).
20. Receiving an investigational anti-cancer treatment concurrently or within 14 days or five half-lives (whichever is shorter) of either the parent drug or any known active metabolite prior to the start of bemcentinib.
21. Unresolved CTCAE \>Grade 2 toxicity (other than stable toxicity) from previous anti-cancer therapy excluding alopecia.
22. Any evidence of severe or uncontrolled systemic conditions (e.g., severe hepatic impairment) or current unstable or uncompensated respiratory or cardiac conditions which makes it undesirable for the participants to participate in the study or which could jeopardize compliance with the protocol.
23. Active, uncontrolled central nervous system (CNS) disease including CNS leukemia.
24. Active infection with human immunodeficiency virus (HIV), hepatitis B or C viruses - screening for viral infections is not required for entry to this study.
25. Major surgery within 28 days prior to the start of bemcentinib - excluding skin biopsies and procedures for insertion of central venous access devices.
26. Hypersensitivity to cytarabine, decitabine or any of its excipients.
27. Prior exposure to Astellas ASP2215 (FLT3/AXL Inhibitor - Gilteritinib).

Primary outcomes:
measure: Part A: Maximum Tolerated Dose (MTD) of Bemcentinib (BGB324)
timeFrame: Cycle 1 (21 days)
measure: Part B: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
timeFrame: Up to 28 days after last dose (up to 1452 days; maximum treatment exposure duration 1424 days)
measure: Part B: Number of Participants With Notable Trends in Physical Examination, Vital Signs, Clinical Laboratory Test and Electrocardiogram (ECG) Values
timeFrame: Baseline to end of the study (Part B: Maximum exposure duration was 1424 days)
Secondary outcomes:
measure: Part A: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
timeFrame: Up to 28 days after last dose (up to 745 days, maximum exposure duration 717 days)
measure: Part A: Number of Participants With Notable Trends in Physical Examination, Vital Signs, Clinical Laboratory Test and Electrocardiogram (ECG) Values
timeFrame: Baseline to end of the study (Part A: Maximum exposure duration was 717 days)
measure: Part A and B: Percentage of Participants With Objective Response (OR) as Per International Working Group Response Criteria
timeFrame: Day 1 of dosing up to end of the study (for Part A: maximum exposure duration 717 days, and for Part B: maximum exposure duration 1424 days)
measure: Part A and B: Percentage of Participants With Stable Disease (SD) as Per International Working Group Response Criteria
timeFrame: Day 1 of dosing up to end of the study (for Part A: maximum exposure duration 717 days, and for Part B: maximum exposure duration 1424 days)
measure: Part A and B: Disease Control Rate (DCR) as Per International Working Group Response Criteria
timeFrame: Day 1 of dosing up to end of the study (for Part A: maximum exposure duration 717 days, and for Part B: maximum exposure duration 1424 days)
measure: Part B: Relapse Free Survival (RFS)
timeFrame: Day 1 of dosing up to end of the study (Part B: maximum exposure duration 1424 days)
measure: Part B: Event Free Survival (EFS)
timeFrame: Day 1 of dosing up to end of the study (Part B: maximum exposure duration 1424 days)
measure: Part B: Overall Survival (OS)
timeFrame: Day 1 of dosing up to end of the study (Part B: maximum exposure duration 1424 days)
measure: Part A and Part B: Pharmacokinetics (PK) Parameter: Area Under The Curve (0-tau) at Steady State (AUCss) for Bemcentinib
timeFrame: Predose, 2, 4, 6 hours post dose on Day 1;predose and 6hours post dose on Day2, predose, 2,4,6,8 hours post dose on Day 3 and predose on Day 4 of Cycle 1; Predose collected on Day1 of each cycle up to and including Cycle 15 and at end of the study (EOS)
measure: Part A and B: Pharmacokinetics Parameter: Maximum Observed Plasma Concentration (Cmax) for Bemcentinib
timeFrame: Pre-dose 2, 4, 6 on Day 1; predose and 6 hours post dose on Day 2; predose, 2, 4, 6 and 8 hours post dose on Day 3 and predose on Day 4 of Cycle 1; Predose collected on Day 1 of each cycle up to and including Cycle 15 and at EOS
measure: Part A and B: Pharmacokinetics Parameter: t1/2 for Bemcentinib
timeFrame: Pre-dose 2, 4, 6 on Day 1; predose and 6 hours post dose on Day 2; predose, 2, 4, 6 and 8 hours post dose on Day 3 and predose on Day 4 of Cycle 1; Predose collected on Day 1 of each cycle up to and including Cycle 15 and at EOS
Other outcomes:
Locations:
city: Iowa City
country: United States
facility: University of Iowa Hospitals and Clinics
state: Iowa
city: Houston
country: United States
facility: The University of Texas M.D. Anderson Cancer Center
state: Texas
city: Hannover
country: Germany
facility: Medizinische Hochschule Hannover,Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation,
state: Carl-Neuberg-Str
city: Hamburg
country: Germany
facility: University Medical Center Hamburg
state: Hamburg-Eppendorf
city: Frankfurt
country: Germany
facility: Frankfurt Medizinische Klinik II, Hämatologie/Onkologie, Haus 33, 2. OG
state: Theodor-Stern-Kai
city: Mannheim
country: Germany
facility: Studienzentrale der Hämatologie/Onkologie III, Medizinische Klinik
city: Ulm
country: Germany
facility: Universitätsklinikum Ulm
city: Cuneo
country: Italy
facility: Azienda Ospedaliera S Croce E Carle, Via Michele Coppino
city: Genoa
country: Italy
facility: Ospedale Policlinico San Martino
city: Lecce
country: Italy
facility: Ospedale Lecce - 'V Fazzi' U. O. Ematologia - P. O. Vito Fazz Piazza Muratore, IV piano Polo Oncologico
city: Parma
country: Italy
facility: Azienda Ospedaliero-Universitaria di Parma
city: Bergen
country: Norway
facility: University of Bergen Department of Clinical Science, Translational Hemato-Oncology group, Faculty of Medicine and Dentistry, Haukelands University Hospital
state: Jonas Lies Vei
Study officials:
affiliation: Universitätsmedizin Mannheim, Universitätsklinikum Mannheim GmbH
name: Sonja Loges, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ben-Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger JS, Riecken K, Binder M, Schewe D, Sawall S, Witzke V, Cubas-Cordova M, Janning M, Wellbrock J, Fehse B, Hagel C, Krauter J, Ganser A, Lorens JB, Fiedler W, Carmeliet P, Pantel K, Bokemeyer C, Loges S. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood. 2013 Oct 3;122(14):2443-52. doi: 10.1182/blood-2013-03-491431. Epub 2013 Aug 27.
citation: Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD; International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003 Dec 15;21(24):4642-9. doi: 10.1200/JCO.2003.04.036.
citation: Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006 Jul 15;108(2):419-25. doi: 10.1182/blood-2005-10-4149. Epub 2006 Apr 11.
citation: Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Lowenberg B, Bloomfield CD. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28.
citation: Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55. No abstract available.
citation: Whitman SP, Kohlschmidt J, Maharry K, Volinia S, Mrozek K, Nicolet D, Schwind S, Becker H, Metzeler KH, Mendler JH, Eisfeld AK, Carroll AJ, Powell BL, Carter TH, Baer MR, Kolitz JE, Park IK, Stone RM, Caligiuri MA, Marcucci G, Bloomfield CD. GAS6 expression identifies high-risk adult AML patients: potential implications for therapy. Leukemia. 2014 Jun;28(6):1252-1258. doi: 10.1038/leu.2013.371. Epub 2013 Dec 11.
citation: Linger RM, Keating AK, Earp HS, Graham DK. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res. 2008;100:35-83. doi: 10.1016/S0065-230X(08)00002-X.
citation: Linger RM, Keating AK, Earp HS, Graham DK. Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opin Ther Targets. 2010 Oct;14(10):1073-90. doi: 10.1517/14728222.2010.515980.
citation: Schmidt T, Ben-Batalla I, Schultze A, Loges S. Macrophage-tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands. Cell Mol Life Sci. 2012 May;69(9):1391-414. doi: 10.1007/s00018-011-0863-7. Epub 2011 Nov 11.
citation: Gjerdrum C, Tiron C, Hoiby T, Stefansson I, Haugen H, Sandal T, Collett K, Li S, McCormack E, Gjertsen BT, Micklem DR, Akslen LA, Glackin C, Lorens JB. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1124-9. doi: 10.1073/pnas.0909333107. Epub 2009 Dec 28.
citation: Korshunov VA. Axl-dependent signalling: a clinical update. Clin Sci (Lond). 2012 Apr;122(8):361-8. doi: 10.1042/CS20110411.
citation: Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, Lee DH, Lee JS, Miller VA, Arcila M, Ladanyi M, Moonsamy P, Sawyers C, Boggon TJ, Ma PC, Costa C, Taron M, Rosell R, Halmos B, Bivona TG. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 2012 Jul 1;44(8):852-60. doi: 10.1038/ng.2330.
citation: Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013 Jan 1;19(1):279-90. doi: 10.1158/1078-0432.CCR-12-1558. Epub 2012 Oct 22.
citation: Safaric Tepes P, Pal D, Lindsted T, Ibarra I, Lujambio A, Jimenez Sabinina V, Senturk S, Miller M, Korimerla N, Huang J, Glassman L, Lee P, Zeltsman D, Hyman K, Esposito M, Hannon GJ, Sordella R. An epigenetic switch regulates the ontogeny of AXL-positive/EGFR-TKi-resistant cells by modulating miR-335 expression. Elife. 2021 Jul 13;10:e66109. doi: 10.7554/eLife.66109.
citation: Meel MH, de Gooijer MC, Metselaar DS, Sewing ACP, Zwaan K, Waranecki P, Breur M, Buil LCM, Lagerweij T, Wedekind LE, Twisk JWR, Koster J, Hashizume R, Raabe EH, Montero Carcaboso A, Bugiani M, Phoenix TN, van Tellingen O, van Vuurden DG, Kaspers GJL, Hulleman E. Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma. Clin Cancer Res. 2020 Jul 1;26(13):3319-3332. doi: 10.1158/1078-0432.CCR-19-3538. Epub 2020 Mar 12.